Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Cairo University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Protara Therapeutics
University of Gaziantep
National Institutes of Health Clinical Center (CC)
AstraZeneca
Tianjin Medical University Second Hospital
University of Iowa
Origin Sciences
Mayo Clinic
Merck Sharp & Dohme LLC
Institut Cancerologie de l'Ouest
Centre Oscar Lambret
AstraZeneca
University of Oklahoma
Janssen Research & Development, LLC
Janssen Pharmaceutical K.K.
University of California, Davis
University of California, Davis
University of Washington
University of Washington
The Methodist Hospital Research Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Institutes of Health Clinical Center (CC)
University of Florida
Pfizer
Poitiers University Hospital
Relmada Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
University of Kansas Medical Center
Mayo Clinic
Bristol-Myers Squibb
H. Lee Moffitt Cancer Center and Research Institute
University Hospitals Bristol and Weston NHS Foundation Trust
M.D. Anderson Cancer Center
CG Oncology, Inc.